An observational study of the impact of long-acting risperidone microspheres on the symptom severity and functional recovery in Maori and Pacific people with schizophrenia and related psychotic disorders

Trial Profile

An observational study of the impact of long-acting risperidone microspheres on the symptom severity and functional recovery in Maori and Pacific people with schizophrenia and related psychotic disorders

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizophrenia and disorders with psychotic features
  • Focus Therapeutic Use
  • Acronyms CIPS
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 17 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top